The Food and Drug Administration issued a notice on Wednesday advising consumers not to inhale nitrous oxide products sold in ...

The US Food and Drug Administration (FDA) has approved treprostinil inhalation powder (YUTREPIA), a prostacyclin analog ...

Liquidia Corporation (NASDAQ:LQDA) announced today that the U.S. Food and Drug Administration (FDA) has approved YUTREPIA ...

This decision came after the full FDA approval of YUTREPIA inhalation powder for adults with pulmonary arterial hypertension ...

Liquidia shares climbed 7.5% after disclosing that it is scheduled to make its first commercial shipment of Yutrepia inhalation powder, days after Food and Drug Administration approval. Shares were ...

Like other inhaled prostaglandins, YUTREPIA may cause acute bronchospasm. Patients with asthma or chronic obstructive pulmonary disease (COPD), or other bronchial hyperreactivity, are at increased ...

The FDA has approved a novel inhalation powder for pulmonary arterial hypertension and interstitial lung disease-associated ...

The FDA has approved Yutrepia, an inhaled treprostinil formulation, for the treatment of PAH and PH-ILD, two forms of ...

received US Food and Drug Administration (FDA) approval for manufacturing and distributing generic Albuterol Sulfate Inhalation Solution, 0.5% (2.5 mg/0.5 mL)* Ritedose is the largest sterile ...